Forensic and Pharmaceutical Risks in the Organization of Pharmacotherapy of Covid, Post-Covid and Long-Covid Disorders. COVID-19 and Vaccination Practice Standards.

Authors

DOI:

https://doi.org/10.53933/sspmpm.v2i4.69

Keywords:

forensic pharmacy, coronavirus, SARS, SARS-CoV-2, COVID-19, pharmacotherapy, post-covid, long-covid, vaccines, standards

Abstract

The COVID-19 pandemic has strained the healthcare system. It is important to consider forensic and pharmaceutical risks in the organization of vaccination practices and pharmacotherapy of covid, post-covid and long-covid disorders. Scientific sources on the clinical characteristics of SARS-CoV-2, COVID-19 have been systematized. The standards of vaccination practice (immunization, vaccination) of different age categories of the population in Ukraine, England, USA, Belgium, Greece, Japan, and Portugal were analyzed. Proven that the organization of pharmacotherapy schemes is difficult due to the presence of mixed infections, comorbid and complicated forms of diseases, the formation of virus resistance to drugs, and the development of secondary immunological insufficiency. The risks of pharmacotherapy with regard to mortality in patients with COVID-19 due to the development of severe lung lesions and systemic multiorgan pathology are indicated. Schemes of combined pharmacotherapy including antiviral, anti-inflammatory drugs, glucocorticosteroids, genetically engineered biological drugs and "targeted" basic anti-inflammatory drugs were analyzed. The theoretical prerequisites for "repositioning" (drug repurposing) for the treatment of COVID-19 and ego complications are indicated. New directions of anti-inflammatory pharmacotherapy of COVID-19 Janus kinase with a range of anti-inflammatory and antiviral effects were noted. Emphasis was placed on the importance of informing health care professionals about forensic pharmaceutical risks in pharmacotherapy and vaccination practices. The relevance of legal support for medical activity in the conditions of a pandemic was noted. Further research is ongoing.

References

Mortality 12 times higher in children with congenital Zika. Medscape Network Medical News. 24.02.2022. URL: https://www.univadis.com/viewarticle/mortality-12-times-higher-children-congenital-zika-2022a1000idy.

McMillan C., Amarilla A., Modhiran N. et al. Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern. Vaccine. 2022. DOI: 10.1016/j.vaccine.2022.07.013. Epub ahead of print. PMID: 35871873. URL: https://www.univadis.com/viewarticle/covid-19-vaccine-patch-more-effective-than-needle-vaccines-against-variants-7e3fd1fa-3875-3cd0-bb77-f7a8a65daad0?sso=true&utm_content=4984957&utm_medium=email&utm_term=&uac=402925HN&ecd=mkm_ret_220811_uniday_MUDGLOBAL_4984957&utm_source=&utm_campaign=medical%20update%20daily.

Shapovalova V.A., Zbrozhek S.I., Shapоvalov V.V. et al. Coronavirus disease pandemia 2019: growth of epidemic dangers. Acta scientific pharmaceutical sciences. 2020. Vol. 4. Iss. 7. P. 61–68. URL: https://www.actascientific.com/ASPS/ASPS-04-0559.php.

Shapovalova V. Monkeypox virus – new challenges of modernity: experimental organizational and legal, clinical and pharmacological studies. SSP Modern Pharmacy and Medicine. 2022. Vol.2. N.3. P.1–15. URL: https://DOI.org/10.53933/sspmpm.v2i3.54.

Shapovalov V. (Jr.), Zbrozhek S., Gudzenko A. et al. Organizational and legal analysis of the pharmaceutical provision for the most common diseases of society. International Journal of Pharmaceutical Sciences Review and Research. 2018. Vol. 51. N. 1. P. 118-124. URL: http://globalresearchonline.net/journalcontents/v51-1/18.pdf.

New clues show how the immune system fights COVID-19. Medscape Network Medical News. 11.05. 2021. URL: https://www.univadis.com/viewarticle/new-clues-show-how-immune-system-fights-covid-19-2021a1000onc.

Vaccines and viral immunology. Harvard Medical School. 05.08.2022. URL: https://onlinelearning.hms.harvard.edu/hmx/hmx-pro/vaccines/?utm_source=google&utm_medium=cpc&utm_campaign=&utm_term=vaccine%20safety&utm_content=540127247496&gclid=Cj0KCQjw_7KXBhCoARIsAPdPTfiwnKfr3ovAeejDfma0l76Lm-vE4tjA9_SXHBGoLCrVWvUOK55nuyMaAoujEALw_wcB.

Weinberger B. Vaccines for the elderly: current use and future challenges. Immun Ageing. 2018. DOI: 10.1186/s12979-017-0107-2. PMID: 29387135. URL: https://www.univadis.com/viewarticle/vaccination-coverage-far-from-optimal-in-older-population.

WHO establishes the Global Centre for Traditional Medicine in India. World Health Organization. 25.03.2022. URL: https://www.who.int/news/item/25-03-2022-who-establishes-the-global-centre-for-traditional-medicine-in-india.

D'Souza J., Nderitu D. Ethical considerations for the modification of routine human papillomavirus immunisation schedules. Lancet Oncol. 20.06.2022. DOI: 10.1016/S1470-2045(22)00367-9. PMID: 35738289.

One-dose Human papillomavirus (HPV) vaccine offers solid protection against cervical cancer. WHO. 11.04.2022. URL: https://www.who.int/news/item/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer.

Single dose of HPV vaccine is 'game changer,' Says WHO. Medscape. 27.07.2022. URL: https://www.univadis.com/viewarticle/who-advisory-group-updated-recommendations-for-hpv-vaccination.

Almost 6,000 vaccinations were given to internally displaced persons in June in 8 regions of Ukraine with the support of WHO. Public Health Center of the Ministry of Health of Ukraine. 25.07.2022. URL: https://www.phc.org.ua/news/mayzhe-6000-scheplen-vnutrishno-peremischenim-osobam-zrobili-v-chervni-u-8-regionakh-ukraini.

Yu J., Ouyang W., Chua K., Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 25.03.2020. DOI: 10.1001/jamaoncol.2020.0980. PMID:32211820. URL: https://www.univadis.com/viewarticle/hospitalized-cancer-patients-may-face-2-fold-greater-risk-of-sars-cov-2-transmission.

Wolff J.A. Direct gene transfer into mouse muscle in vivo. Science. 23.03.1990. DOI: 10.1126/science.1690918.

Jackson L.A. An mRNA vaccine against SARS-COV-2 – preliminary report. The New England Journal of medicine. 14.07.2020. DOI: 10.1056/NEJMoa2022483.

Peck K.M., Lauring A.S. Complexities of viral mutation rates. J. Virol. 2018. DOI: 10.1128/JVI.01031-17. URL: https://journals.asm.org/DOI/10.1128/jvi.01031-17.

Pepini T. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J. Immunol. 2017. Vol.198. No.10. P.4012-4024. DOI: 10.4049/jimmunol.1601877.

Theofilopoulos A.N. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev. Immunol. 2005. No.23. P.307-336. DOI: 10.1146/annurev.immunol.23.021704.115843.

Ulutas H., Celik M.R., Gulcek I. et al. Management of spontaneous pneumothorax in patients with COVID-19. Interact Cardiovasc Thorac Surg. 18.10.2021. DOI: 10.1093/icvts/ivab280. PMID: 34661670. URL: https://www.univadis.com/viewarticle/covid-19-management-of-spontaneous-pneumothorax.

Chatham-Stephens K., Vogt T., Grusich K., Carnes A. Add Routine and COVID-19 vaccination to the back-to-school checklist. Medscape. 28.07. 2022. URL: https://www.medscape.com/viewarticle/977916.

Bjork A., Morelli V. Immunization strategies for healthcare practices and providers. CDC. 2021. No.8. Р.29-42. URL: https://www.cdc.gov/vaccines/pubs/pinkbook/strat.html.

Priya J. Vaccines explained. VaccinesWork. 28.04.2021. URL: https://www.gavi.org/vaccineswork/vaccines-explained?utm_campaign=Campaign%203&utm_medium=Medium%201&utm_source=Source%2017&gclid=Cj0KCQjw_7KXBhCoARIsAPdPTfhthnoXYQBd1I_iQRlN3euvGT9R8ArzKWWnnQ8ZPp918GM2BRjj_fwaAkhdEALw_wcB.

Immunization coverage. WHO. 14.07.2022. URL: https://www.who.int/news-room/fact-sheets/detail/immunization-coverage.

Vaccination coverage for children and mothers. Nuffieldtrust. 31.03.2022. URL: https://www.nuffieldtrust.org.uk/resource/vaccination-coverage-for-children-and-mothers-1

Zbrozgek S. Reform of the healthcare system as a basis for streamlining the organization of circulation and availability of medicines for patients in the context of the COVID-19 pandemic. SSP Modern Pharmacy and Medicine. 2021. Vol. 1. No. 2. P. 1-32. URL: https://DOI.org/10.53933/sspmpm.v1i2.31.

Hayduchok І. Рharmacotherapy of systemic autoimmune diseases in conditions of the COVID-19 pandemic: innovative experimental study. Science Review. 2021. Vol. 3. No. 38. P. 1-7. DOI:10.31435/rsglobal_sr/30072021/7619.

Hayduchok І., Shapovalov V. Covid-19: multidisciplinary researches of forensic and pharmaceutical risks and causal relationships of unqualified medical care for patients during pandemic. 2022. SSP Modern Law and Practice. Vol.2. N.1. P.1-25. URL: https://DOI.org/10.53933/sspmlp.v2i1.39.

COVID pandemic fuelling major increase in drug use worldwide: UN report. United Nations. URL: https://news.un.org/en/story/2021/06/1094672.

Shapovalova V. The ICD-11 for the twenty-first century: the first view from the organizational, legal, clinical and pharmacological aspects. SSP Modern Pharmacy and Medicine. 2022. Vol.2. N.1. P.1-13. URL: https://DOI.org/10.53933/sspmpm.v2i1.37.

Shapovalov V.V. (Jr.), Shapovalova V.A., Shapovalov V.V. Development of forensic and pharmaceutical researches within the organization of pharmaceutical business, drug technology and pharmaceutical law in Ukraine concerning the turnover of controlled drugs and substances. Health of Society. 2021. Vol.10. Nо.3. P.98-106. URL: https://DOI.org/10.22141/2306-2436.10.3.2021.246351.

Shapovalov V.V. (Jr.), Shapovalova V.A., Shapovalov V.V. Forensic and pharmaceutical research on the impact of drugs on the safety, life and health of road users within the organization of pharmaceutical business, drug technology, pharmaceutical and medical law in Ukraine. Health of Society. 2021. Vol.10. Nо.4. P.127-132. URL: https://DOI.org/10.22141/2306-2436.10.4.2021.246355.

Shapovalova V., Zakharchenko I. Organizational and legal approaches to reforming of the law enforcement system of Ukraine: illegal circulation of psychoactive substances and addictive dependence. 2021. SSP Modern Law and Practice. Vol. 1. Nо.1. P.1–22. URL: https://DOI.org/10.53933/sspmlp.v1i1.20.

Shapovalov (Jr.) V., Gudzenko A., Shapovalova V. et al. Forensic and pharmaceutical analysis of addictive morbidity because of the use of narcotic psychoactive substances in Ukraine (retrospective aspect). International Journal of Pharmaceutical Sciences and Research. 2018. Vol. 3. Is.3. July 2018. P.22-25. URL: http://www.pharmacyjournal.net/archives/2018/vol3/issue3.

Shapovalova V.A., Shapovalov V.V. The clinical efficacy of the combined drug agent Valcophen in children. Likars'ka sprava. 1999. Nо.1. P.124–126.

Shapovalova V.O., Mykhailov V.S., Shapovalov V.V. The characteristics of the development of cataleptic phenomena during the action of a new Ukrainian neuroleptic--a butyrophenone derivative--in experiments on mice. Fiziolohichnyi zhurnal. 1999. Vol.45. Nо.3. P. 114–117.

Shapovalova V.O., Shapovalov V.V. Spasmophilia in children and the anticonvulsant properties of a new Ukrainian preparation containing a pyrimidine derivative. Fiziolohichnyi zhurnal. 1998. Vol.44. Nо.5-6. P. 102–105.

Shapovalova V.O., Chernykh V.P. The physiological properties of the action of a new analgesic and antipyretic preparation. Fiziolohichnyi zhurnal. 1997. Vol.43. Nо.1-2. P. 117–121.

Shapovalov V. (Jr.), Gudzenko А., Komar L. et al. Concerning the importance of forensic and pharmaceutical researches to improve patients’ accessibility to medicines. Pharmacia. 2017. Vol.65. Nо.2. P.23–29. URL: http://bsphs.org/wp-content/uploads/2017/07/Shapovalov.pdf.

Shapovalov V. (Jr.), Gudzenko A., Shapovalova V. at. el. Forensic and pharmaceutical study of the presence of a causal link between the degree of alcohol abuse and qualification level of the respondents. Pharmacia. 2017. Vol.66. Nо.3. Р. 31–39. URL: http://bsphs.org/wp-content/uploads/2017/11/Shapovalov.pdf.

Shapovalov V.V. (Jr.), Zbrozhek S.I., Shapovalova V.O. et al. Organizational and legal evaluation of availability of medicines’ circulation for cancer patients Pharmacia. 2018. Vol.65. Nо.2. P.17-22. URL: http://bsphs.org/?magasine=organizational-and-legal-evaluation-of-availability-of-medicines-circulation-for-cancer-patients.

McGill L. Patient safety: a European Union priority. Clin Med (Lond). 2009. Vol.9. N.2. Р.136-139. DOI: 10.7861/clinmedicine.9-2-136. URL: https://pubmed.ncbi.nlm.nih.gov/19435118/.

Tukhar I., Shapovalova V., Shapovalov V. et al. Pharmacological view on the problem of comorbidity in the pharmacotherapy of chronic pancreatitis. Science Review. Vol.3. No.38. P.1-5. DOI: 10.31435/rsglobal_sr/30072021/7591.

Shapovalov V., Butko L., Shapovalov V. Organizational and legal study of quarantine restrictions in the spread of coronavirus disease in Ukraine. SSP Modern Pharmacy and Medicine. 2021. Vol.1. N.2. P.1–12. URL: https://DOI.org/10.53933/sspmpm.v1i2.23.

Madewell Z.J., Yang Y., Longini I.M. et al. Factors associated with household transmission of SARS-CoV-2: an updated systematic review and meta-analysis. JAMA Network Open. 27.08.2021. DOI: https://DOI.org/10.1001/jamanetworkopen.2021.22240. URL: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783544.

Modjarrad K., Roberts C.C., Mills K.T. et al. Safety and immunogenicity of an anti-мiddle еast respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019. DOI:10.1016/ S1473-3099(19)30266-x. Published online 24.07.2019. URL: https://www.univadis.com/viewarticle/mers-cov-vaccine-is-safe-and-induces-strong-immunity-in-first-in-human-trial.

National vaccine advisory committee (NVAC). URL: https://www.hhs.gov/vaccines/nvac/index.html.

New сlues show how the іmmune system fights COVID-19. Medscape Network Medical News. 11.05.2021. URL: https://www.univadis.com/viewarticle/new-clues-show-how-immune-system-fights-covid-19-2021a1000onc.

Рівень охоплення щепленнями в Україні нижче 40%: медики б'ють на сполох і закликають вакцинувати дітей. УНН. 04.08.2022. URL: https://www.ukrinform.ua/rubric-society/3543847-mediki-but-na-spoloh-z-pocatku-roku-seplennami-ohopleno-mens-ak-40-ditej.html.

Vardanjani H.M., Borna H., Ahmadi A. Effectiveness of pneumococcal conjugate vaccination against invasive pneumococcal disease among children with and those without HIV infection: a systematic review and meta-analysis. BMC Infect Dis. 2019. Vol.19. No.1. P.685. DOI: 10.1186/s12879-019-4325-4. PMID: 31382917. URL: https://www.univadis.com/viewarticle/pcv-vaccine-less-effective-among-young-hiv-infected-children.

Wahl B., O'Brien K.L., Greenbaum A. et al. Burden of Streptococcus pneumoniae and haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018. Vol.6. No.7. P.e744-e757. DOI: 10.1016/S2214-109X (18)30247-X. PMID: 29903376. URL: https://www.univadis.com/viewarticle/hib-and-pneumococcal-vaccines-save-1-35-million-children-since-2000.

Trantham L., Kurosky S.K., Zhang D., Johnson K.D. Adherence with and completion of recommended hepatitis vaccination schedules among adults in the United States. Vaccine. 13.06.2018. DOI: 10.1016/j.vaccine.2018.05.111. PMID: 29909136. URL: https://www.univadis.com/viewarticle/hepatitis-a-b-vaccination-series-completion-adherence-low-among-us-adults.

Jacob S., Veenstra-Vander Weele J., Murphy D. et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet. 2022. S2215036621004296. URL: https://DOI.org/10.1016/S2215-0366(21)00429-6. PMID: 35151410. URL: https://www.univadis.com/viewarticle/balovaptan-for-adults-with-autism-spectrum-disorder.

Deng Z., Qin Y., Wang J. et al. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis. Clin Genet. 21.08.2019. DOI: 10.1111/cge.13628. PMID: 31432497. URL: https://www.univadis.com/viewarticle/meta-analysis-supports-mmr-screening-in-colorectal-cancer.

The Guide to Tailoring immunization Programmes. WHO. URL: https://www.euro.who.int/__data/assets/pdf_file/0003/187347/The-Guide-to-Tailoring-Immunization-Programmes-TIP.pdf.

Dionne A., Sperotto F., Chamberlain S. et al. Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. JAMA Cardiol. 2021. https://DOI.org/10.1001/jamacardio.2021.3471.

Capeding MR.Z., Gatchalian S.R., Aseron M. et al. Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study. Expert Rev Vaccines. 07.03.2022. DOI: 10.1080/14760584.2022.2046469. PMID:35220869. URL: https://www.univadis.com/viewarticle/phase-4-study-confirms-dtwp-hbv-hib-vaccine-safety-in-pediatric-patients.

Hemmers L. Systematic review and meta-analysis of vaccine effectiveness of two-dose measles vaccination: high enough for elimination? Abstract 02556. To be presented at the 2022 32nd Annual European Society of Clinical Microbiology and Infectious Diseases on 23-26 April 2022. URL: https://www.univadis.com/viewarticle/europe-loses-ground-on-measles-elimination.

Gold J.E., Baumgartl W.H., Okyay R.A. et al. Analysis of мeasles-мumps-rubella (MMR) тiters of recovered COVID-19 рatients. MBio. 2020. URL: https://DOI.org/10.1128/mBio.02628-20. URL: https://www.univadis.com/viewarticle/measles-mumps-rubella-may-reduce-covid-19-severity.

European мedicines аgency. Meeting highlights from the Committee for мedicinal рroducts for human use. 22.07.2022. URL: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022.

Kwon K.J., Timmons A.E., Sengupta S. et al. Different human resting memory CD4(+) T cell subsets show similar low inducibility of latent HIV-1 proviruses. Sci Transl Med. 29.01.2020. DOI: 10.1126/scitranslmed. aax6795. PMID:31996465. URL: https://www.univadis.com/viewarticle/different-human-resting-memory-cd4-t-cell-subsets-show-similar-low-inducibility-of-latent-hiv-1-proviruses.

Lau DC.W., Erichsen L., Francisco A.M. et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021. DOI: 10.1016/S0140-6736(21)01751-7. PMID: 34798060. URL: https://www.univadis.com/viewarticle/new-once-weekly-obesity-drug-achieves-significant-weight-loss.

Tseng H.F., Sy L.S., Ackerson B.K. et al. Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy. Vaccine. 15.06.2022. DOI: 10.1016/j.vaccine.2022.06.009. PMID: 35717267. URL: https://www.univadis.com/viewarticle/prenatal-tetanus-diphtheria-and-pertussis-vaccination-safe.

Chappell C.A. Universal hepatitis C virus screening in pregnancy: the juice is worth the squeeze. Conference on Retroviruses and Opportunistic Infections (CROI 2022) on 14 February 2022. URL: https://www.univadis.com/viewarticle/croi-2022--study-supports-universal-hcv-screening-of-pregnant-women.

European centre for disease prevention and control, and European monitoring centre for drugs and drug addiction. Public health guidance on active case finding of communicable diseases in prison settings. Prevention and control of communicable diseases in prison setting. 2018. DOI: 10.2900/619331. URL: https://ecdc.europa.eu/sites/portal/files/documents/Active-case-finding-communicable-diseases-in-prisons.pdf.

Shapovalova V. An Innovative multidisciplinary study of the availability of coronavirus vaccines in the world. SSP Modern Pharmacy and Medicine. 2022. Vol.2. N.2. P.1–17 URL: https://DOI.org/10.53933/sspmpm.v2i2.45.

Shapovalov V.V., Shapovalov Valentin V. (Jr.), Shapovalova V.A. Pharmaceutical and medical law: textbook. allowance (series: Pharmaceutical law). Kharkov: Publishing House "Scorpion", 2011. 208 p.

Galatsan O.V., Shapovalova V.O., Shapovalov V.V. Pharmaceutical law in the state system of minimizing legal and pharmaceutical risks in the circulation of medicinal products in rural areas. Ukraine Journal of Psychoneurology. 2013. T. 21. Issue 2 (75). P. 96-100. URL: https://uvnpn.com.ua/arkhiv-nomeriv/2013/tom-21-vipusk-2-75/farmatsevtichne-pravo-v-derzhavn-y-sistem-m-n-m-zats-sudovo-farmatsevtichnikh-rizik-v-pri-ob-gu-l-ka.

Ivanishyn-Hayduchok L., Shapovalova V., Shapovalov V. ICD-11: Organizational and legal, medical and pharmaceutical, social and economic issues of implementation of the program of state guarantees of medical care in 2022 in Ukraine, based on the fundamental principles of the European Union. SSP Modern Pharmacy and Medicine. 2022. Vol.2. N.2. Р.1–14. URL: https://DOI.org/10.53933/sspmpm.v2i2.53.

Shapovalov V.V., Shapovalova V.O., Shapovalov V.V. et al. Medychne ta farmatsevtychne pravo: navch. posib. dlia dodyplomnoi ta pisliadyplomnoi formy navchannia. Seriia «Medychne ta farmatsevtychne pravo». 4-e vyd. zi zminamy ta dopovnenniamy. Kharkiv –Ivano-Frankivsk: KhMAPO, 2020. 128 s.

Hayduchok I., Shapovalov V. Forensic pharmacy and medicine: risks for pharmacotherapy of addiction and countering of illegal circulation of psychoactive substances in the COVID-19 pandemic. 2021. SSP Modern Pharmacy and Medicine. Vol.1. N.2. P.1-28. URL: https://DOI.org/10.53933/sspmpm.v1i2.32.

Hayduchok І., Shapovalov V. Covid-19: multidisciplinary researches of forensic and pharmaceutical risks and causal relationships of unqualified medical care for patients during pandemic. 2022. SSP Modern Law and Practice. Vol.2. N.1. P.1-25. URL: https://DOI.org/10.53933/sspmlp.v2i1.39.

Large clinical trial will test combination monoclonal antibody therapy for mild/moderate COVID-19. National institute of allergy and infectious diseases. 05.01.2021. URL: https://www.nih.gov/news-events/news-releases/large-clinical-trial-will-test-combination-monoclonal-antibody-therapy-mild-moderate-covid-19/.

WHO. Solidarity trial consortium. Repurposed antiviral drugs for COVID-19. Interim WHO SOLIDARITY trial results. Infectious Diseases. 2020. URL: https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1.

Boushra M., Koyfman A., Long B. COVID-19 in pregnancy and the puerperium: a review for emergency physicians. Am. J. Emerg. Med. 31.10.2020. DOI: 10.1016/j.ajem.2020.10.055. URL: https://www.univadis.com/viewarticle/pregnancy-and-covid-19-comorbidities-boost-risk-for-severe-disease.

Regierer A. Older age, cardiovascular comorbidity and glucocorticosteroids are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic diseases: first results of the German COVID-19-IRD registry. European League Against Rheumatism. 05.06.2020. URL: https://www.univadis.com/viewarticle/eular-2020-risk-factors-for-covid-19-hospitalization-in-patients-with-inflammatory-rheumatic-diseases.

Ebinger J., Driver M., Joung S. et al. Hypertension and excess risk for severe COVID-19 illness despite booster vaccination. Hypertension. 20.07.2022. DOI: 10.1161/HYPERTENSIONAHA.122.19694. PMID: 35862106.

Elkrief A. High mortality among hospital-acquired COVID-19 infection in patients with cancer: an observational cohort study from Quebec and British Columbia. AACR Virtual Meeting: COVID-19 and Cancer 2020. 13.08.2020 URL: https://www.univadis.com/viewarticle/higher-death-rate-in-cancer-patients-with-nosocomial-covid-19.

COVID-19: U.S. Impact on аntimicrobial resistance. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2022. URL: https://www.cdc.gov/drugresistance/covid19.html.

Virta J.J., Strbian D., Putaala J., Korja M. Risk of aneurysm rupture after thrombolysis in patients with acute ischemic stroke and unruptured intracranial aneurysms. Neurology. 2021. DOI: 10.1212/WNL.0000000000012771. PMID: 34615686. URL: https://pubmed.ncbi.nlm.nih.gov/34615686/.

Ray W.A., Chung C.P., Stein C.M. et al. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021. Vol.326. No.23. P.2395-2404. DOI: 10.1001/jama.2021.21222. PMID: 34932078. URL: https://jamanetwork.com/journals/jama/fullarticle/2787319.

Zarifkar P., Peinkhofer C., Benros M.E., Kondziella D. Frequency of neurological diseases after COVID-19, influenza A/B and bacterial pneumonia. Front Neurol. 2022. DOI: 10.3389/fneur.2022.904796. PMID: 35812108.

Wölfel R., Corman V.M., Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020. DOI: 10.1038/s41586-020-2196-x. URL: https://www.nature.com/articles/s41586-020-2196-x.

World Health Organization Regional Office for Africa. Expert panel endorses protocol for COVID-19 herbal medicine clinical trials. 19.09.2020. URL: https://www.univadis.com/viewarticle/preparing-for-clinical-trials-of-herbal-medicine-for-covid-19.

Karoyan P., Vieillard V., Gómez-Morales L. et al. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. Communications Biology. 2021. No.4. P.1–9. URL: https://DOI.org/10.1038/s42003-021-01736-8.

Patriquin G., LeBlanc J., Gillis H.A. et al. Combined oropharyngeal/nares and nasopharyngeal swab sampling remain effective for molecular detection of SARS-CoV-2 Omicron variant. medRxiv. 15.02.2022. DOI: 10.1101/2022.02.13.22270891. URL: https://www.univadis.com/viewarticle/covid-19-nasal-throat-swabs-both-effective-for-sars-cov-2-omicron-detection.

Chen H., Guo J., Wang C. et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 12.02.2020. DOI: 10.1016/S0140-6736(20)30360-3. URL: https://www.univadis.com/viewarticle/coronavirus-covid-19-no-evidence-of-mother-to-baby-transmission.

Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Resp Med. 24.02.2020. DOI: 10.1016/S2213-2600(20)30079-5. URL: https://www.univadis.com/viewarticle/covid-19-high-mortality-among-critically-ill-pneumonia-patients-in-wuhan.

Petherick A. Developing antibody tests for SARS-COVID-2. The Lancet. 04.04.2020. URL: https://DOI.org/10.1016/S0140-6736(20)30788-1. URL: Developing antibody tests for SARS-CoV-2 - The Lancet.

Corcoran M. WHO to revew pain management guidelines. 27.08.2019. URL: https://www.univadis.com/viewarticle/who-to-review-pain-management-guidelines.

Cao B., Wang Y., Wen D. et al. A Trial of lopinavir-ritonavir in adults Hospitalized with Severe COVID-19. N. Engl. J. Med. 18.03.2020. DOI: 10.1056/NEJMoa2001282. PMID: 32187464. URL: https://www.univadis.com/viewarticle/lopinavir-ritonavir-offers-no-survival-benefit-in-adults-hospitalized-with-severe-covid-19.

Mild COVID-19 infection linked to later type 2 diabetes. Medical news. 21.03.2022. URL: https://www.univadis.com/viewarticle/mild-covid-19-infection-linked-later-type-2-diabetes-2022a1000qt0.

Tandler C. Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency. American Association for Cancer Research (AACR) Annual Meeting. 12.04.2022. URL: https://www.univadis.com/viewarticle/hematologic-cancer-novel-covid-19-vaccine-induces-t-cell-immune-response.

Bravo C. COVID-19 аround the world weekly highlights: at risk of new wave, continued pressure of COVID-19 on hospitals, and the new XE recombinant variant. Medical news. 08.04.2022. URL: https://www.univadis.com/viewarticle/covid-19-around-the-world-weekly-highlights-at-risk-of-new-wave-continued-pressure-of-covid-19-on-hospitals-and-the-new-xe-recombinant-variant.

Shunqing Xu., Yuanyuan Li. Beware of the second wave of COVID-19. Lancet. 08.04.2020. DOI: 10.1016/ S0140-6736(20)30845-X. URL: https://www.univadis.com/viewarticle/preparing-for-a-second-wave-of-covid-19.

Bhimraj A., Morgan R., Shumaker A. IDSA Guidelines on the treatment and management of patients with COVID-19. IDSA. 22.02.2022. URL: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/.

Sanchis-Gomar F., Lavie C.J., Perez-Quilis C. et al. Angiotensin-сonverting еnzyme 2 and аnti-hypertensives (аngiotensin receptor вlockers and аngiotensin сonverting еnzyme іnhibitors) in Coronavirus Disease 2019 (COVID-19). Mayo Clinic Proceedings. 2020. Vol.95. Іssue 6. DOI: 10.1016/j.mayocp.2020.03.026. URL: https://www.univadis.com/viewarticle/ace-inhibitors-and-arbs-in-covid-19-a-review-of-the-evidence.

Colavita F. SARS-CoV-2 іisolation from оcular secretions of a рatient with COVID-19 in Italy with рrolonged viral RNA detection. Ann Intern Med. 2020. DOI: 10.7326/M20-1176. URL: https://www.univadis.com/viewarticle/covid-19-sars-cov-2-isolated-in-ocular-secretions.

COVID-19 Update. Elusive сomplication, remdesivir toxicity. Medical news. 08.07.2020. URL: https://www.univadis.com/viewarticle/covid-19-update-elusive-complication-remdesivir-toxicity-2020a1000cwz.

Recovery Collaborative Group. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 05.10.2020. DOI: 10.1016/S0140-6736(20)32013-4. URL: https://www.univadis.com/viewarticle/covid-19-no-benefit-with-lopinavir-ritonavir-in-moderate-severe-disease.

Tam A.R., Zhang R.R., Lung K.C. et al. Early treatment of high-risk hospitalized COVID-19 patients with a combination of interferon beta-1b and remdesivir: a phase 2 open-label randomized controlled trial. Clin Infect Dis. 28.06.2022. DOI: 10.1093/cid/ciac523. PMID: 35762834. URL: https://www.univadis.com/viewarticle/covid-19-interferon-beta-1b-plus-remdesivir-effective-for-hospitalized-patients.

Mazeraud A., Jamme M., Mancusi R. et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021. URL: https://DOI.org/10.1016/S2213-2600(21)00440-9. URL: https://www.univadis.com/viewarticle/iv-immunoglobulins-ineffective-for-covid-19-acute-respiratory-distress-syndrome.

O’Shea D. Valsartan: review of impurities extended to other sartan medicines. European Medicines Agency. 21.09.2018. URL: https://www.univadis.com/viewarticle/losartan-investigation-of-contamination-with-possible-carcinogen.

Park S.W., Kim T.J., Lee J.Y. et al. Comorbid immune‐mediated diseases in inflammatory bowel disease: a nation‐wide population‐based study. Aliment Pharmacol Ther. 02.12.2018. DOI: 10.1111/apt.15076. URL: https://www.univadis.com/viewarticle/ibd-5-asa-tied-to-lower-odds-of-comorbid-immune-mediated-disease.

Progress in хenotransplantation оpens door to new supply of сritically needed оrgans. Newswise. 21.10.2021. URL: https://www.newswise.com/articles/progress-in-xenotransplantation-opens-door-to-new-supply-of-critically-needed-organs.

In a first, surgeons attached a pig kidney to a human — and it worked. DNyuz. 19.10.2021. URL: https://dnyuz.com/2021/10/19/in-a-first-surgeons-attached-a-pig-kidney-to-a-human-and-it-worked/.

Growing еvidence supports repurposing antidepressants to treat COVID-19. Medscape Network Medical News. 17.11.2021. URL: https://www.univadis.com/viewarticle/growing-evidence-supports-repurposing-antidepressants-treat-2021a1002czd.

Rhee S., Lee J., Nam H. et al. Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. Diabetes Metab. J. 05.03.2021. DOI: 10.4093/dmj.2020.0206. PMID: 33752274. URL: https://www.univadis.com/viewarticle/covid-19-dpp-4-inhibitors-are-linked-to-improved-outcomes.

Mandeep R., Ruschitzka F., Patel A. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 04.06. 2020. https://DOI.org/10.1016/S0140-6736(20)31324-6. URL: https://www.univadis.com/viewarticle/lancet-retracts-controversial-covid-19-chloroquine-study.

Mehra M.R., Desai S.S., Ruschitzka F., Pate A.N. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 22.05.2020. https://DOI.org/10.1016/S0140-6736(20)31180-6. URL: https://www.univadis.com/viewarticle/covid-19-6-continent-study-finds-increased-mortality-risk-with-hydroxychloroquine.

Ramakrishnan S., Nicolau D., Langford B. et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. The Lancet Respiratory Medicine. 2021. https://DOI.org/10.1016/S2213-2600(21)00160-0. URL: https://www.univadis.com/viewarticle/covid-19-inhaled-glucocorticoids-may-be-an-effective-treatment.

Dolci G. Methylprednisolone рulses in hospitalized рatients with severe COVID-19 рneumonia. Conference on retroviruses and оpportunistic іnfections. 16.02.2022. URL: https://www.univadis.com/viewarticle/croi-2022--covid-19-pneumonia-methylprednisolone-pulse-therapy-added-to-dexamethasone-shows-no-benefit.

Sinha P., Matthay M.A., Calfee C.S. Is a "Cytokine Storm" relevant to COVID-19? JAMA Intern Med. 30.06.2020. DOI: 10.1001/jamainternmed.2020.3313. PMID: 32602883. URL: https://www.univadis.com/viewarticle/cytokine-storm-op-ed-examines-the-utility-of-the-term-for-covid-19.

EMA recommends approval for use of Kineret in adults with COVID-19. European Medicines Agency (EMA). 16.12.2021. URL: https://www.ema.europa.eu/en/news/ema-recommends-approval-use-kineret-adults-covid-19.

Lauper K., Mongin D., Bergstra S. et al. Comparative effectiveness of JAK-inhibitors, TNF-inhibitors, abatacept and IL-6 inhibitors in an international collaboration of registers of rheumatoid arthritis patients (The "JAK-pot" Study). European League Against Rheumatism (EULAR). 05.06.2020. URL: Abstract OP0231.

JAK Inhibitors Go the Distance in RA Patients. Medscape.09.06.2020. URL: https://www.univadis.com/viewarticle/eular-2020-jak-inhibitors-maintained-for-longer-in-patients-with-ra.

Shapovalov V., Butko L., Shapovalov V. Organizational and legal study of quarantine restrictions in the spread of coronavirus disease in Ukraine. SSP Modern Pharmacy and Medicine. 2021. Vol. 1. N. 2. P. 1–12. URL: https://DOI.org/10.53933/sspmpm.v1i2.23

Shapovalova V., Shapovalov V., Shapovalov Valentyn et al. The COVID-19 pandemic (strains "Delta", "Omicron"): particularities of study on the thematic cycle "General Pharmacy based on pharmaceutical law". Actual problems of medicine and pharmacy. 2022. Vol.3. N.1. Р.1–18. URL: https://DOI.org/10.52914/apmp.v3i1.36

Hayduchok І., Shapovalov V., Shapovalov Valentyn. Organizational and legal study and implementation by administrative staff of higher education of licensing conditions for educational activities in Ukraine during COVID-19 pandemic. Actual problems of medicine and pharmacy. 2022. Vol. 3. N.1. Р.1–30. URL: https://DOI.org/10.52914/apmp.v3i1.38

Shapovalova V., Shapovalov V., Shapovalov Valentyn et al. Experience of the department of medical and pharmaceutical law, general and clinical pharmacy of the Kharkiv medical academy of postgraduate education concerning the educational process during the quarantine period caused by COVID-19. Actual problems of medicine and pharmacy. 2021. Vol.2. N.2. Р.1–20. URL: https://DOI.org/10.52914/apmp.v2i2.33

Shapovalova V., Shapovalov V., Osyntseva A. et al. Organization of the pharmaceutical business, industrial pharmacy and forensic pharmacy concerning the competences of quality management during the circulation of medical products: GxP standards. Actual problems of medicine and pharmacy. 2022. Vol.3. N. 2. P.1–20. URL: https://DOI.org/10.52914/apmp.v3i2.44

Shapovalov V., Veits O. Forensic and pharmaceutical, criminal and legal, social and economic study of the conditions, that cause bribery corruption in the system of legal relations "doctor-patient-investigator-lawyer". SSP Modern Law and Practice. 2022. Vol.2. No.3. P.1-16. URL: https://DOI.org/10.53933/sspmlp.v2i3.57

Shapovalov V. Forensic pharmacy, organization of pharmaceutical business, drug technology, medical, pharmaceutical and criminal law: the state system of combating the illegal circulation of narcotic drugs and psychotropic substances and their abuse in pandemic condition. SSP Modern Law and Practice. 2022. Vol.2. No.3. P.1-35. URL: https://DOI.org/10.53933/sspmlp.v2i3.66

Shapovalov V.V., Shapovalov Valentin V. (Jr.), Shapovalova V.A. Pharmaceutical and medical law: textbook. allowance (series: Pharmaceutical law). Kharkov: Publishing House "Scorpion", 2011. 208 p.

Shapovalov V. Medical and pharmaceutical law: deepening the cooperation between the LMI, KhMAPE* and Estonian Scientific Publishing House SSP OÜ, as part of the system of Ukraine’s integration into the European Community. SSP Modern Law and Practice. 2022. Vol.2. No.2. P.1-12. URL: https://DOI.org/10.53933/sspmlp.v2i2.51.

Downloads

Published

2022-10-19

How to Cite

Shapovalova, V. (2022). Forensic and Pharmaceutical Risks in the Organization of Pharmacotherapy of Covid, Post-Covid and Long-Covid Disorders. COVID-19 and Vaccination Practice Standards. SSP Modern Pharmacy and Medicine, 2(4), 1–24. https://doi.org/10.53933/sspmpm.v2i4.69

Issue

Section

Health Sciences